Related Experiment Video
Updated: Jun 29, 2026

Analyzing the Permeability of the Blood-Brain Barrier by Microbial Traversal through Microvascular Endothelial Cells
Published on: February 14, 2020
Methylglyoxal mediates vascular inflammation via JNK and p38 in human endothelial cells
Hideyuki Yamawaki1, Kazuaki Saito, Muneyoshi Okada
1Dept. of Veterinary Pharmacology, Kitasato University., Towada, Aomori 034-8628, Japan. yamawaki@vmas.kitasato-u.ac.jp
Abstract:
Methylglyoxal (MGO) is a reactive metabolite of glucose. Since the plasma concentration of MGO is increased in diabetic patients, MGO is implicated in diabetes-associated vascular endothelial cells (ECs) injury, which might be responsible for atherosclerosis. In the present study, we examined effects of treatment of human umbilical vein ECs with MGO on EC morphology and inflammatory responses. MGO (24 h) induced cytotoxic morphological changes in a concentration-dependent manner (0-420 microM). MGO induced mRNA and protein expression of cyclooxygenase (COX)-2 in a concentration (0-420 microM)- and time (6-24 h)-dependent manner. COX-2 induction was associated with increased PGE(2) release. Acute treatment with MGO (20 min) induced concentration-dependent (0-420 microM) activation of JNK and p38 MAP kinase but not ERK or NF-kappaB. Both the JNK inhibitor SP600125 and the p38 inhibitor SB203580 prevented the MGO induction of COX-2. However, inhibiting JNK and p38 or COX-2 was ineffective to the morphological damage by MGO (420 microM, 24 h). EUK134, a synthetic combined superoxide dismutase/catalase mimetic, had no effect on MGO-induced COX-2. Present results indicated that MGO mediates JNK- and p38-dependent EC inflammatory responses, which might be independent of oxidative stress. On the other hand, MGO-induced morphological cell damage seems unlikely to be associated with COX-2-PGE(2).
Insights
Methylglyoxal (MGO), a glucose metabolite elevated in diabetes, causes vascular endothelial cell (EC) damage. MGO triggers inflammatory responses via JNK and p38 pathways, but these pathways do not mediate MGO-induced cell damage.
Area of Science:
- Biochemistry
- Cell Biology
- Vascular Biology
Background:
- Methylglyoxal (MGO) is a reactive glucose metabolite.
- Elevated plasma MGO is observed in diabetic patients.
- MGO is implicated in diabetes-associated vascular endothelial cell (EC) injury and atherosclerosis.
Purpose of the Study:
- To investigate the effects of MGO treatment on human umbilical vein ECs.
- To examine MGO's impact on EC morphology and inflammatory responses.
Main Methods:
- Treatment of human umbilical vein ECs with varying concentrations of MGO (0-420 microM) for different durations (20 min to 24 h).
- Assessment of EC morphology, cyclooxygenase-2 (COX-2) mRNA and protein expression, PGE(2) release, and MAP kinase (JNK, p38, ERK) and NF-kappaB activation.
- Utilized JNK and p38 inhibitors (SP600125, SB203580) and a superoxide dismutase/catalase mimetic (EUK134) to elucidate pathways.
Main Results:
- MGO induced concentration-dependent cytotoxic morphological changes in ECs.
- MGO upregulated COX-2 expression and PGE(2) release in a concentration- and time-dependent manner.
- MGO activated JNK and p38 MAP kinases but not ERK or NF-kappaB; JNK and p38 inhibition prevented COX-2 induction, but not morphological damage.
Conclusions:
- MGO mediates JNK- and p38-dependent inflammatory responses in ECs, potentially independent of oxidative stress.
- MGO-induced morphological cell damage appears to be independent of the COX-2/PGE(2) pathway.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Inflammatory Response I: Vascular and Cellular
MAPK Signaling Cascades
Acute Inflammation III: Local and Systemic Effects
Nitric Oxide Signaling Pathway